CXCR4 and cancer: CXCR4 inhibitors are currently in clinical trials as anti-cancer therapeutics (e.g. ALX-0651 [NCT01374503], MSX-122 [NCT00591682], BMS-936564 [NCT02305563, NCT01359657, NCT01120457, NCT02472977]) [23].